PMC:7461420 / 25170-26048
Annnotations
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T146 | 57-65 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T147 | 430-440 | Disease | denotes | arrhythmia | http://purl.obolibrary.org/obo/MONDO_0007263 |
T148 | 582-590 | Disease | denotes | COVID‐19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T149 | 711-730 | Disease | denotes | autoimmune diseases | http://purl.obolibrary.org/obo/MONDO_0007179 |
T150 | 735-742 | Disease | denotes | malaria | http://purl.obolibrary.org/obo/MONDO_0005136 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T280 | 106-107 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T281 | 193-194 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T282 | 843-844 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T230 | 119-137 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T231 | 141-152 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T232 | 195-204 | Chemical | denotes | macrolide | http://purl.obolibrary.org/obo/CHEBI_25106 |
T233 | 213-225 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
T234 | 230-244 | Chemical | denotes | clarithromycin | http://purl.obolibrary.org/obo/CHEBI_3732 |
T235 | 344-348 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T236 | 522-527 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
T237 | 621-632 | Chemical | denotes | chloroquine | http://purl.obolibrary.org/obo/CHEBI_3638 |
T238 | 637-655 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
T239 | 821-839 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T10 | 418-440 | Phenotype | denotes | ventricular arrhythmia | http://purl.obolibrary.org/obo/HP_0004308 |
T11 | 711-730 | Phenotype | denotes | autoimmune diseases | http://purl.obolibrary.org/obo/HP_0002960 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
822 | 43-51 | Species | denotes | patients | Tax:9606 |
823 | 308-316 | Species | denotes | patients | Tax:9606 |
824 | 373-381 | Species | denotes | patients | Tax:9606 |
825 | 119-137 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
826 | 141-152 | Chemical | denotes | chloroquine | MESH:D002738 |
827 | 195-204 | Chemical | denotes | macrolide | MESH:D018942 |
828 | 213-225 | Chemical | denotes | azithromycin | MESH:D017963 |
829 | 230-244 | Chemical | denotes | clarithromycin | MESH:D017291 |
830 | 621-632 | Chemical | denotes | chloroquine | MESH:D002738 |
831 | 637-655 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
832 | 821-839 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
833 | 57-65 | Disease | denotes | COVID‐19 | MESH:C000657245 |
834 | 418-440 | Disease | denotes | ventricular arrhythmia | MESH:D001145 |
835 | 582-590 | Disease | denotes | COVID‐19 | MESH:C000657245 |
836 | 711-730 | Disease | denotes | autoimmune diseases | MESH:D001327 |
837 | 735-742 | Disease | denotes | malaria | MESH:D008288 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T240 | 0-246 | Sentence | denotes | The recent clinical trial involving 96 032 patients with COVID‐19 concluded that it was unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or in combination with a macrolide such as azithromycin (or clarithromycin). |
T241 | 247-358 | Sentence | denotes | 82 The study actually reported decreased survival rates for patients treated with each of these drug regimens. |
T242 | 359-457 | Sentence | denotes | Additionally, patients had an increased risk of developing ventricular arrhythmia under treatment. |
T243 | 458-744 | Sentence | denotes | However, still more evidence is needed to adequately assess the drugs' risks or benefits for the treatment or prevention of COVID‐19 (it is important to note that chloroquine and hydroxychloroquine are still considered safe treatment options in certain autoimmune diseases and malaria). |
T244 | 745-878 | Sentence | denotes | Besides, the WHO announced the premature pause of its clinical trials using hydroxychloroquine as a safety precaution on 24 May 2020. |